Completed Enrollment

A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)] (ALPACA)

J3L-MC-EZEB -

The main purpose of this study is to determine the efficacy and safety of LY3819469 in adults with elevated lipoprotein (a).

Trial Summary

Age Range
≥40 years
Conditions the trial is for
Lipoprotein Disorder
What the trial is testing?
LY3819469
Could I receive a Placebo?
Yes
Enrollment Goal
216
Trial Dates
Oct 20, 2022 - Oct 2024
How long will I be in the trial?
The study will last about 20 months and may include up to 13 visits.
Trial Phase
II

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must be at least 40 years old and have Lp(a) level≥175 nmol/L at screening

  • Participants if on lipid-lowering drugs or hormone therapy need to be on stable dose for at least 4 weeks prior to screening

  • A body mass index within the range 18.5 to 40 kilogram/square meter 

  • Males who agree to use highly effective contraception methods or women not of childbearing age

Participants Must Not:

  • Have a history or presence of an underlying disease, or surgical, physical, medical, or psychiatric condition that in the opinion of the investigator, would affect participant safety within the study or interfere with participating in or completing the study or with the interpretation of data.

  • Had major surgery within 3 months of day 1

  • Had coronary, carotid, or peripheral arteria revascularization, stroke, heart attack or chest pain within 3 months of day 1

  • Have uncontrolled diabetes

  • Have uncontrolled high blood pressure

  • Women of childbearing potential

Lilly Trial Alerts

Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.

Clinical Trial Resources